Clinical and Immunologic Aspects of Cytomegalovirus Infection in Solid Organ Transplant Recipients
- 1 February 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 79 (4) , 381-386
- https://doi.org/10.1097/01.tp.0000148239.00384.f0
Abstract
Primary cytomegalovirus (CMV) infection is a major cause of morbidity and mortality in recipients after solid organ transplantation (SOT). Widespread and prolonged use of antiviral drugs has changed the natural course of CMV disease by delaying its onset and causing drug resistance. CMV induces a strong cellular immune response, even in immunosuppressed patients, and has developed strategies to evade this immune surveillance. This review summarizes challenges in managing CMV infection in transplant recipients and highlights current insights in the cellular immune response against CMV.Keywords
This publication has 75 references indexed in Scilit:
- Human Cytomegalovirus Elicits a Coordinated Cellular Antiviral Response via Envelope Glycoprotein BJournal of Virology, 2004
- Cytomegalovirus (CMV) Glycoprotein B Genotypes and Response to Antiviral Therapy, in Solid‐Organ–Transplant Recipients with CMV DiseaseThe Journal of Infectious Diseases, 2003
- Epidermal growth factor receptor is a cellular receptor for human cytomegalovirusNature, 2003
- Diagnosis and treatment approaches of CMV infections in adult patientsJournal of Clinical Virology, 2002
- Clinical Aspects and Management of Cytomegalovirus InfectionJournal of Infection, 2002
- Epidemiology and Management of Infections after Lung TransplantationClinical Infectious Diseases, 2001
- The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantationNephrology Dialysis Transplantation, 2000
- CYTOMEGALOVIRUS DISEASE RECURRENCE AFTER GANCICLOVIR TREATMENT IN KIDNEY AND KIDNEY-PANCREAS TRANSPLANT RECIPIENTSTransplantation, 1999
- MAJOR INFECTIOUS COMPLICATIONS AFTER ORTHOTOPIC LIVER TRANSPLANTATION AND COMPARISON OF OUTCOMES IN PATIENTS RECEIVING CYCLOSPORINE OR FK506 AS PRIMARY IMMUNOSUPPRESSIONTransplantation, 1995
- SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2Transplantation, 1992